Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...

Eli Lilly is expanding its pain drug ... collaborator and investor in the startup, though an alliance on NaV1.7 drugs ended when the pharma giant exited neuroscience R&D. Late last year, Novo ...

Sidekick is also working with a number of other pharma companies on companion ... and other chronic conditions. The new Lilly alliance is one of three that Sidekick expects to announce in the ...

demonstrati Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain.

In its second R&D alliance this week, Eli Lilly has formed a partnership with ... Earlier this week, the pharma group announced a $1 billion alliance with Swiss start-up Haya Therapeutics to ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

By Priya Kalia, SciTribe and Miranda Weston-Smith, BioBeat.

Of Florida’s 30-member delegation, at least seven don’t own, buy or sell stocks, nor do their spouses or dependent children, a Playbook review of public records showed. They include GOP Reps. KAT ...